- Home
- GNPX vs KPRX Comparison
GNPX vs KPRX Comparison
Compare GNPX & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNPX
- KPRX
- Stock Information
- Founded
- GNPX 2009
- KPRX 1998
- Country
- GNPX United States
- KPRX United States
- Employees
- GNPX N/A
- KPRX N/A
- Industry
- GNPX Biotechnology: Pharmaceutical Preparations
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- GNPX Health Care
- KPRX Health Care
- Exchange
- GNPX Nasdaq
- KPRX Nasdaq
- Market Cap
- GNPX 10.8M
- KPRX 9.2M
- IPO Year
- GNPX 2018
- KPRX N/A
- Fundamental
- Price
- GNPX $6.64
- KPRX $2.53
- Analyst Decision
- GNPX
- KPRX Strong Buy
- Analyst Count
- GNPX 0
- KPRX 1
- Target Price
- GNPX N/A
- KPRX $10.00
- AVG Volume (30 Days)
- GNPX 1.7M
- KPRX 48.4K
- Earning Date
- GNPX 11-14-2025
- KPRX 11-07-2025
- Dividend Yield
- GNPX N/A
- KPRX N/A
- EPS Growth
- GNPX N/A
- KPRX N/A
- EPS
- GNPX N/A
- KPRX N/A
- Revenue
- GNPX N/A
- KPRX N/A
- Revenue This Year
- GNPX N/A
- KPRX N/A
- Revenue Next Year
- GNPX N/A
- KPRX N/A
- P/E Ratio
- GNPX N/A
- KPRX N/A
- Revenue Growth
- GNPX N/A
- KPRX N/A
- 52 Week Low
- GNPX $6.51
- KPRX $2.21
- 52 Week High
- GNPX $140.00
- KPRX $4.18
- Technical
- Relative Strength Index (RSI)
- GNPX 63.07
- KPRX 45.20
- Support Level
- GNPX $7.71
- KPRX $2.21
- Resistance Level
- GNPX $9.89
- KPRX $2.68
- Average True Range (ATR)
- GNPX 1.15
- KPRX 0.16
- MACD
- GNPX 0.53
- KPRX -0.02
- Stochastic Oscillator
- GNPX 50.54
- KPRX 50.00
About GNPX Genprex Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.